Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma) (Q73270056)
Jump to navigation
Jump to search
scientific article published on 01 October 1999
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma) |
scientific article published on 01 October 1999 |
Statements
Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma) (English)
M R Sertoli
P Queirolo
E Bajetta
M Del Vecchio
G Comella
L Barduagni
M G Bernengo
S Vecchio
D Criscuolo
R Bufalino
A Morabito